Business

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”). Background on the Original Warrant Transaction As previously announced, on November 26, 2025, EUDA

articleEuda Health Holdings LimitedJanuary 7, 20263/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-110000504
EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

About this update from Euda Health Holdings Limited

[{"type":"text","content":"SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”).","length":400,"tagName":"p"},{"type":"text","content":"Background on the Original Warrant Transaction","length":46,"tagName":"p"},{"type":"text","content":"As previously announced, on November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital, a Utah limited liability company, for the issuance of a warrant (the “Warrant”) exercisable into up to 2,000,000 newly issued ordinary shares of EUDA for an aggregate purchase price of US$100,000. The Warrant was issued on December 4, 2025. The offer and sale of the Warrant and the Warrant Shares were made pursuant to a prospectus supplement dated December 4, 2025, as part of a registration statement on Form F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on November 4, 2024. The Warrant may be exercised for cash for ninety (90) days (unless extended by the parties) from the date of issuance (the “Cash Exercise Period”). At the end of two weeks after the Cash Exercise Period has expired, Streeterville Capital will automatically be deemed to have made a “cashless” exercise of the Warrant, and the Company will be required to issue to Streeterville Capital one (1) ordinary share for every ten (10) outstanding Warrant Shares for no additional consideration.","length":1174,"tagName":"p"},{"type":"text","content":"Summary of Amended Terms","length":24,"tagName":"p"},{"type":"text","content":"On December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant from US$6.00 per share to US$4.00 per share and (ii) reduce the minimum closing price required to trigger a “Forced Exercise” (defined in the Warrant) from US$7.50 to US$6.00. All other terms of the warrant remain unchanged.","length":360,"tagName":"p"},{"type":"text","content":"About EUDA Health Holdings Limited","length":34,"tagName":"p"},{"type":"text","content"...

More updates from Euda Health Holdings Limited

EUDASINGAPOREThe Companyoutstanding Warrantordinary sharesStreetervilleWarrant